Synthetic RIG-I agonist-mediated cancer immunotherapy synergizes with MAP-Kinase inhibition against BRAF mutated melanoma [YUMM1.7]
RNA-seq (gene expression) · mouse · 15 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 15 samples: 15 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Synthetic RIG-I agonist-mediated cancer immunotherapy synergizes with MAP kinase inhibition against BRAF-mutated melanomaMolecular therapy. Nucleic acids · 2024
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE269008_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1119955 and SRA study SRP511603. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 15 sample titles: 15 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8304769 Melanoma murin, no stimulation, no inhibitor, 24h, rep1
- GSM8304770 Melanoma murin, transfection control, no inhibitor, 24h, rep1
- GSM8304771 Melanoma murin, 3pRNA, no inhibitor, 24h, rep1
- GSM8304772 Melanoma murin, no stimulation, dabrafenib, 24h, rep1
- GSM8304773 Melanoma murin, transfection control, dabrafenib, 24h, rep1
- GSM8304774 Melanoma murin, 3pRNA, dabrafenib, 24h, rep1
- GSM8304775 Melanoma murin, no stimulation, trametinib, 24h, rep1
- GSM8304776 Melanoma murin, transfection control, trametinib, 24h, rep1
- GSM8304777 Melanoma murin, 3pRNA, trametinib, 24h, rep1
- GSM8304778 Melanoma murin, no stimulation, vehicle, 24h, rep1
- GSM8304779 Melanoma murin, transfection control, vehicle, 24h, rep1
- GSM8304780 Melanoma murin, 3pRNA, vehicle, 24h, rep1
- GSM8304781 Melanoma murin, no stimulation, dabrafenib+trametinib, 24h, rep1
- GSM8304782 Melanoma murin, transfection control, dabrafenib+trametinib, 24h, rep1
- GSM8304783 Melanoma murin, 3pRNA, dabrafenib+trametinib, 24h, rep1
- GSE286241 BRAF inhibition increases TGFb2 production and stimulates metastasis in mice with endogenous BRAFV600E-induced hepatocellular carcinoma 12 samples shares braf, inhibition
- GSE276771 A stem-loop RNA RIG-I agonist induces immunogenic death and vascular remodeling to potentiate cancer immunotherapy 10 samples shares rig-i, immunotherapy
- GSE288791 BRAF/MEK Inhibition Induces Cell State Transitions Boosting Immune Checkpoint Sensitivity in BRAFV600E-mutant Glioma 1 samples shares braf, inhibition
- GSE64102 Improved antitumor activity of immunotherapy combined with BRAF and MEK inhibitors in BRAFV600E mutant melanoma 13 samples shares braf, immunotherapy
- GSE279468 Gene expression profile at single cell level of Braf-mutant mouse melanoma tumor and skin 53 samples shares braf
- GSE296998 Novel syngeneic cell lines for studying high-risk BRAFV600E-driven colorectal cancer in vivo [RNA-seq_NaJa] 34 samples shares braf
- GSE227189 Single cell transcriptomic analyses of the dynamic local and systemic response to cardiac injury in mice and zebrafish [mouse] 28 samples shares braf
- GSE296999 Novel syngeneic cell lines for studying high-risk BRAFV600E-driven colorectal cancer in vivo [RNA-seq_organoids] 28 samples shares braf
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.